IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.369
NA - Nord America 4.407
AS - Asia 3.239
SA - Sud America 404
Continente sconosciuto - Info sul continente non disponibili 261
AF - Africa 42
OC - Oceania 7
Totale 15.729
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.116
US - Stati Uniti d'America 4.277
SG - Singapore 1.086
IT - Italia 801
CN - Cina 647
IE - Irlanda 601
HK - Hong Kong 564
VN - Vietnam 392
BR - Brasile 340
DE - Germania 244
KR - Corea 185
GB - Regno Unito 171
IN - India 113
FR - Francia 77
JP - Giappone 75
CA - Canada 73
UA - Ucraina 65
SE - Svezia 51
FI - Finlandia 38
NL - Olanda 35
GR - Grecia 33
BD - Bangladesh 31
PK - Pakistan 30
TR - Turchia 29
AT - Austria 28
PL - Polonia 26
AR - Argentina 23
MX - Messico 21
CZ - Repubblica Ceca 17
BE - Belgio 16
ID - Indonesia 15
LT - Lituania 15
CR - Costa Rica 12
IQ - Iraq 12
EC - Ecuador 11
ES - Italia 11
ZA - Sudafrica 11
AZ - Azerbaigian 9
CO - Colombia 9
MA - Marocco 7
UZ - Uzbekistan 7
AU - Australia 6
HN - Honduras 6
PY - Paraguay 6
SA - Arabia Saudita 6
VE - Venezuela 6
KE - Kenya 5
TN - Tunisia 5
CH - Svizzera 4
GT - Guatemala 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
MK - Macedonia 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
TH - Thailandia 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
CL - Cile 2
EE - Estonia 2
EG - Egitto 2
GI - Gibilterra 2
IR - Iran 2
JM - Giamaica 2
LK - Sri Lanka 2
SN - Senegal 2
SV - El Salvador 2
TW - Taiwan 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
LC - Santa Lucia 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
Totale 15.463
Salva come PNG Salva come JPEG
Città #
Moscow 1.834
San Jose 735
Dublin 586
Hong Kong 548
Singapore 526
Santa Clara 450
Ashburn 390
Chandler 282
Council Bluffs 242
Seoul 184
Naples 162
Ho Chi Minh City 133
Dallas 111
Jacksonville 110
Hefei 109
Beijing 107
New York 100
Los Angeles 95
Hanoi 94
Milan 90
Munich 69
Bremen 68
Princeton 66
Roxbury 66
Bengaluru 57
The Dalles 53
Caserta 43
Cambridge 38
North Charleston 36
São Paulo 34
Ann Arbor 33
Chicago 32
Medford 29
Rome 28
Boardman 24
Da Nang 24
Haiphong 24
Warsaw 24
Wilmington 23
Brooklyn 21
Tokyo 21
Atlanta 20
Miano 19
Nuremberg 19
Amsterdam 16
Brno 16
Elora 16
Montreal 16
Des Moines 15
San Francisco 15
Vienna 15
Denver 14
Falkenstein 14
Las Vegas 13
Napoli 13
Brussels 12
Chennai 12
Houston 12
Hải Dương 12
Orem 12
Piscataway 12
Toronto 12
Woodbridge 12
Aversa 11
London 11
North Bergen 11
Rio de Janeiro 11
Shanghai 11
Lappeenranta 10
Rawalpindi 10
San José 10
Seattle 10
Turku 10
Baku 9
Belo Horizonte 9
Bologna 9
Frankfurt am Main 9
Hillsboro 9
Istanbul 9
Manchester 9
Memphis 9
Phoenix 9
San Mateo 9
Buffalo 8
Columbus 8
Ercolano 8
Kochi 8
Ninh Bình 8
Vilnius 8
Brasília 7
Helsinki 7
Jinan 7
Nanjing 7
Pozzuoli 7
Stockholm 7
Tianjin 7
Bari 6
Boston 6
City of London 6
Dong Ket 6
Totale 8.334
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 239
AXL is an oncotarget in human colorectal cancer 205
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 203
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 200
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 200
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 190
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 187
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 182
Immunotherapy for head and neck cancer: Present and future 182
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 175
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 174
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 172
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 172
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 171
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 171
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 168
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 168
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 168
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 167
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 167
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 167
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 165
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial 164
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 163
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 163
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 163
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 162
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 161
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 161
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 160
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 160
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 159
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 158
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 155
Clinical management of metastatic colorectal cancer in the era of precision medicine 155
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 155
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 154
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 152
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 152
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 152
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 151
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 149
Pimasertib hydrochloride 149
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 148
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 147
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 147
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 145
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 144
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 142
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 142
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 140
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 140
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 139
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 138
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 137
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 137
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 137
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 136
Prevention of cardiovascular complications in elderly cancer patients 135
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 134
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 132
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 132
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 132
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 131
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 131
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 131
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 131
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 130
Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review 127
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 127
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 126
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 126
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 124
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 124
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 123
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 122
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 122
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 122
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 120
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 120
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 120
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 119
It is finally time for adjuvant therapy in melanoma 119
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 119
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 118
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 118
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 118
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 114
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 114
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 113
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 111
How we treat locoregional melanoma 110
Obesity correlates to the microsatellite instability of endometrial cancer: A retrospective observational study 109
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 106
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 104
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 104
Targeting the EGFR signalling pathway in metastatic colorectal cancer 103
Novel in vitro cancer models for optimizing anti- EGFR therapies 103
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 102
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 102
Totale 14.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.385
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.385
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022480 0 0 0 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/20252.156 52 53 30 98 295 295 277 221 265 242 182 146
2025/20269.049 382 448 431 353 743 4.753 565 449 378 284 145 118
2026/20271.586 75 268 593 650 0 0 0 0 0 0 0 0
Totale 15.729